Genomics team members from MPLN, Inc. including Isabel Hubbard, M.Sc., and Drs. Alice Layton and Bevan Tandon recently presented at the 2016 Association for Molecular Pathology annual meeting on the relative utility of Next Generation Sequencing for evaluation of IgVH somatic hypermutation in CLL/SLL. NGS confers significant advantages compared to traditional methodologies, and a clinically validated assay is now available from MPLN.
Contact client services to order the test.
Click here for more information and to download a copy of the poster
Commenting is turned off for this post.
Commenting is not available in this channel entry.